The following is an excerpt.
Critics who think the U.S. Patent Office has been too liberal in awarding protection for naturally occurring phenomena like human genes are watching Association for Molecular Pathology v. Myriad Genetics closely for signs the U.S. Supreme Court will tighten controls in this area. It’s an easy position to sympathize with; how can someone own the rights to a human gene?
But Myriad raises tough questions, including what happens to the 100,000 or so genetic patents already awarded.
Read the full story: The Curious Case of Human Gene Patents
